Effects of triptorelin versus placebo on the symptoms of endometriosis

Bergqvist A, A Bergqvist, Agneta Bergqvist, T. Bergh, Bergh T, Hogström L, Lars Hogström, L Hogström, S.E. Mattsson, S Mattsson, Mattsson S, F Nordenskjöld, Nordenskjöld F, Fredrik Nordenskjöld, Carsten Rasmussen, Rasmussen C, C Rasmussen
Fertility and sterility · 1998 · vol. 69(4) , pp. 702–708 · doi:10.1016/s0015-0282(98)00019-3 · PMID:9548161 · W2073040347
RCT OA: closed CC0 ⤵ 75 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the effects of triptorelin compared to placebo on the symptoms of endometriosis, assessing treatment efficacy and tolerability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To compare the effect of a GnRH-agonist, triptorelin, versus placebo on the symptoms of endometriosis. DESIGN: A prospective, randomized, double-blind study of 6 months of treatment followed by 12 months of follow-up. SETTING: Departments of Obstetrics and Gynecology at two universities and one general hospital. PATIENT(S): Forty-nine women with symptoms of laparoscopically verified endometriosis. INTERVENTION(S): Triptorelin depot or placebo was given every 4 weeks. Clinical evaluation, including the Duration Intensity Behavior Scale and Visual Analogue Scale for pain, was performed before the injections and up to 12 months after treatment. A control laparoscopy was performed 4-6 weeks after the last injection. MAIN OUTCOME MEASURE(S): Quantitation of pain. RESULT(S): Twenty-four patients had active treatment and 25 received placebo. Pain symptoms according to both scales were significantly more reduced after 2 months of triptorelin treatment compared to placebo. The extent of endometriotic lesions was reduced 50% during triptorelin treatment and increased 17% during placebo. The average area of endometriotic lesions was reduced 45% during triptorelin treatment but was unchanged during placebo. Side effects, mainly hot flushes, were experienced by 80% of the actively treated group but also by 33% of patients in the placebo group. Because of recurrent symptoms, only five patients could be observed for 12 months after completion of treatment. CONCLUSION(S): Triptorelin reduces endometriotic lesions and pain to a significantly higher degree than placebo.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Luteolytic Agents Pain Measurement Pelvic Pain Triptorelin Pamoate Adult Adult Delayed-Action Preparations Delayed-Action Preparations Double-Blind Method Double-Blind Method Endometriosis Endometriosis Endometriosis Female Female Follow-Up Studies Follow-Up Studies Humans Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (22)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T22:00:35.617750+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0 · commercial use OK